Ibrutinib Shows Promise in Treating GVHD After Stem Cell Transplant
Ibrutinib has showed clinically meaningful and durable responses in patients with chronic graph-versus-host-disease (cGVHD).
More Treatment Does Not Necessarily Mean More Benefit in Multiple Myeloma
A second round of chemotherapy or stem cell transplant for patients with multiple myeloma does not improve PFS or OS compared to the current standard couse of treatment.
Endocrine Therapy Plus Ovarian Suppression Remains An Effective Treatment Strategy in HR+, HER2-, Early Breast Cancer
Investigators Present Real-World Experiences With T-DXd Following HER2 Status Changes
Maintenance Pembrolizumab/Olaparib Falls Short in Locally Advanced, Metastatic TNBC
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
2 Clarke Drive Cranbury, NJ 08512